Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 4/20 | 0.56 |
| ▸ | CNR2 | P34972 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14411640 | 0.90 | HTR7 (0.58) | HTR7CNR2KCNH2 | |
| SCHEMBL5451025 | 0.88 | HTR7 (0.61) | HTR7CNR2KCNH2 | |
| SCHEMBL5450012 | 0.87 | CNR1 (0.56) | L3MBTL1CNR2KMT2ACNR1 | |
| SCHEMBL5450951 | 0.85 | HTR7 (0.55) | HTR7CNR2 | |
| SCHEMBL5452863 | 0.84 | KCNH2 (0.57) | L3MBTL1CNR2KCNH2KMT2ACNR1 | |
| SCHEMBL14412209 | 0.84 | HTR7 (0.52) | HTR7CNR2KCNH2KMT2AOPRM1 | |
| SCHEMBL5446903 | 0.83 | CREBBP (0.56) | HTR7CNR2CNR1 | |
| SCHEMBL14411478 | 0.83 | HTR7 (0.51) | HTR7CNR2CNR1 | |
| SCHEMBL5460398 | 0.81 | L3MBTL1 (0.56) | L3MBTL1CNR2KMT2ACNR1 | |
| SCHEMBL5451082 | 0.81 | MAPK1 (0.60) | L3MBTL1CNR2KMT2ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007079239-A2 | BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | L3MBTL1 4494/4885HTR7 269/4885CNR2 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.